Novaliq’s Vevizye (Ciclosporin) gains the CHMP’s Positive Opinion to Prevent Moderate to Severe Dry Eye Disease (DED)
Shots:
-
The CHMP has granted a positive opinion to Vevizye in moderate to severe dry eye disease adults treated with tear substitutes based on (ESSENCE-1 & ESSENCE-2) trials involving >1500 patients
-
Vevizye showed improved ocular surface health, with a reduction in corneal fluorescein staining at D15 (~71.6% responded within 4wks.); additional benefits were observed at up to 56wks., verifying its efficacy & tolerability
-
Vevizye (CyclASol) is a clear, 0.1% ciclosporin solution without oils, surfactants, or preservatives offering superior spreading and longer retention on the eye
Ref: Novaliq | Image: Novaliq
Related News:- Novaliq Reports the EMA Acceptance of MAA for CyclASol (ciclosporin ophthalmic solution) to Treat Dry Eye Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
